Search

Displaying results 6441 - 6450 of 10000 in total
  1. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.

  2. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.

  3. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    (6-9) that is important for binding to the known melanocortin receptors. … It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis.

  4. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    PCL-016 plays a key role in zinc transport. … As a therapeutic agent, the molecule works by binding to zinc finger proteins (ZFPs) in a way that changes their structures and disrupts zinc binding, inhibiting function.

    Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingSynonyms: 2-Carboxypyridine
  5. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen is a benzopyran with potential antineoplastic activity. … Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  6. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease prog...

  7. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. … AG-858 (autologous heat-shock protein 70 peptide vaccine) is a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.

  8. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  9. Drug

    MM-093

    go.drugbank.com/drugs/DB05512
    Investigational

    Current studies are assessing MM-093’s potential to improve the treatment of autoimmune disease. … Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy.

  10. Drug

    Managlinat dialanetil

    go.drugbank.com/drugs/DB05518
    Investigational

    CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.